The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
ONLY NEED numbers and more interest and obd will rerate
Is the start of the long road back to 20p SP?
What pun?
complete and utter load of ******, excuse the pun!!!
On a positive, it's still progress.
It definitely helps to highlight the product and the clientele of such a prestiges practice could include Royalty to politicians so it's quite a shroud move on their part
Dug
They can’t and won’t because the number of sales is still pathetic
They are not enough to sustain the day to day running costs of the company .
Too many friends and family on the payroll
Nomads to freighted to tell them otherwise
The strategy of the company is ridiculous
Burrows and leaches have no business ideas
Next-up the RNS announcing seminars to try tompersuade London Clinic doctors to use potentially life changing tests ahead of regulatory approval. The patients already have 'access'. This is BUPA in miniature.
Show us some actual sales please.
London clinic won't necessarily generate a lot of income we by itself, however it will help keep the lights on and definitely will generate a lot of positive knowledge spread which is key. The Transform project is a slow moving behemoth of a study which will make its conclusions known in 2 years, and I suspect there is a market for a leading non invasive test in parallel with mri before that, the London clinic endorsing pse is exactly that,
RNS 💤💤💤💤
Does look like a company that despite having what they claim are great products put the cart before the horse across the board and tried to run before it could jump. Financials are complete mess as a result. Overheads must mean they are burning through cash at an amazing rate. As for the CFO, who can forget his reply to shareholders concerns about refinancing the company when the shares were I think @20p levels and he stated "we have always been able to raise funds at a premium"....that didn't exactly work out as he expected then. Feels like they thought customers would be smashing down their doors to buy their tests just because they kept telling everyone how good they are.
Such a shame that what should be a fantastic British scientific success story has been so ineptly managed by those in charge. They might yet get it right but will it be in time to avoid another discounted funding round?
Hashi Ahmed's main interest is MRI imaging and he only appears as a co-author on some OBD publications by virtue of his leading role in the Prostogram trial (OBD were ancillary participants in Prostogram).
Prof Eeles has the most relevant expertise to push a case for inclusion of PSE tests but the lancet publication I recently referenced suggests that Stockholm3 is the preferred genetic marker technology included.
Burrows said OBD's participation in Transform was crucial but he has failed to act accordingly. Thankfully we can jump from prostate cancer to rheumatoid arthritis as the latest propaganda bandwagon.
No focus, no strategy, no sales, plenty of placings.
Kingalf
Aim is a joke, but it has allowed itself to become a joke because they have not policed it properly.
The nomads are also to blame because they haven’t policed their clients properly.
And Oxford is a typical example.
The CEO has blatantly and falsely led shareholders wrongly.
The nomads have let them do this, because they are frightened of loosing the revenue from the client . I.E ( Oxford )
It’s a disgrace this has been allowed to happen and in my opinion both the nomads and Oxford should be made accountable by AIM.
Only then will AIM get some integrity back !!
Https://prostatecanceruk.org/research/transform-trial#:~:text=TRANSFORM%20update%2C%20May%202024,in%20time%20for%20a%20cure.
This has been updated with the list of primary researchers, Hashim Ahmed at Imperial is referenced in the 2019 OBD pse trial. Thus means that clearly The researchers in Transform are well aware of the pse test, and presumably will give it weight when evaluating the psa test alongside the other screening options. The Transform project also states that there are 16 co-applicants not currently announced so there is ample scope still to be included.
Last chance is the Transform trials.
Sooo much promise and none of it reflected in the share price. AIM is definitely the wild west of investing, and should carry a health warning.
I was reading an article yesterday where the FCA is prosecuting so C list celebraties for promoting CFD contracts. Apparently 80% of participants lose money. Surely the AIM market is not that far off
Getting flushed down the pan before our very eyes!!!@
If they need a raise when this is 1p if will decimate existing holders!!!@
Have they got anything that makes a worthwhile profit!!??
It's starting to sadly look like a prime example of a lifestyle company with a big mix of nepotism thrown in. The only saving grace is that the bods are feeling the pain as much as the PI, but sadly unlike the bods our monthly pay isn't softening the blow. Back to hope
I think
I suspect
Perhaps
These are words used when you don't know, but just assume, theorise and project it from ones backside. None of us know jack, proof being the pickle were in so if he wants to remain positive, who are you to be in a position to dampen it with some out the backside suggestions!
@Lincolnite.
In case you missed it, last year the company CEO was telling us that sales were growing exponentially when subsequent updates revealed they had actually gone down from very few to negligible by year end. This latest statement by the CSO most probably reflects the characteristic scattergun approach to tje market rather than an uplift in sales 'across many fields'. The latter would require that they have abandoned the stated priorities for this year which are that two new VP's were to target inclusion of CiRT and PSE in medical guidance notes for the US in order to boost sales of these "flagship" products. It would also suggest that any new products being 'rapidly adopted' do not require regulatory approval, otherwise we would surely have seen appropriate RNS announcements? I suspect he means a handful of early adopter medics have bought a handful of tests to explore potential, but unconfirmed, benefits across multiple fields.
I'm especially encouraged by the statement from Dr Alexandre Akoulitchev, CSO at OBD: "With fast adoption of EpiSwitch 3D genomic biomarkers across many fields". This suggests that sales are going well. The Interim Results should be out in around two weeks' time, so it'll be nice to have this confirmed then.
Interim results end of May?? ?
I’ve lost another fortune here ffs
Yep 123456789, certainly can see the market loved it.
Looks like a move to justify the wages of Burrows and his cronies. Look forward to the tweet from lazy bones on £55,000.